<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2023">
  <stage>Registered</stage>
  <submitdate>26/06/2008</submitdate>
  <approvaldate>26/06/2008</approvaldate>
  <nctid>NCT00706771</nctid>
  <trial_identification>
    <studytitle>Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study</studytitle>
    <scientifictitle>A Randomized Double-blind Controlled Pilot Feasibility and Safety Trial of NGAL-directed Sodium Bicarbonate to Protect Renal Function in Patients With the Systemic Inflammatory Response Syndrome, Oliguria and Elevated Lipocalin Levels</scientifictitle>
    <utrn />
    <trialacronym>BLISS</trialacronym>
    <secondaryid>TNH 18/08</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Systemic Inflammatory Response Syndrome</healthcondition>
    <healthcondition>Oliguria</healthcondition>
    <healthcondition>Renal Impairment</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Sodium bicarbonate
Treatment: drugs - Sodium chloride

Active Comparator: Sodium bicarbonate - sodium bicarbonate: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr

Active Comparator: Sodium chloride - sodium chloride: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr


Treatment: drugs: Sodium bicarbonate
Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr

Treatment: drugs: Sodium chloride
0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The ability to deliver the study protocol safely and rapidly with a trend to improved renal outcomes</outcome>
      <timepoint>28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Attenuation in lipocalin levels</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Decrease in the magnitude in serum creatinine rise</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ability to deliver the study protocol without significant biochemical side effects</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Consent obtained

          -  Diagnosis of SIRS. Requires any TWO of:

        temperature &gt; 38°C or &lt; 36°C OR heart rate &gt; 90 beats/min OR respiratory rate &gt; 20
        breaths/min. PaCO2 &lt; 32 mm Hg OR alteration of white blood cell count &gt; 12,000 cells/mm3, &lt;
        4,000 cells/mm3, or the presence of &gt; 10% immature neutrophils

          -  elevated lipocalin level

          -  Arterial line already in place

          -  Central venous catheter already in place

          -  Age = 18 years

          -  Within 24 hours of admission to the ICU</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Unlikely to remain in ICU for &gt;72 hours

          -  Moribund patient

          -  Pre-existing CKD, transplant or ESRD

          -  Receiving (or about to receive) continuous renal replacement therapy for acute renal
             failure at time of enrolment

          -  Diagnosis of acute GN, AIN, vasculitis or post-renal aetiology

          -  Known/suspected study allergy to sodium bicarbonate

          -  Enrolling physician concern about patient enrolment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Austin Hospital - Heidelberg, Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <postcode>3084 - Heidelberg, Melbourne</postcode>
    <postcode>3154 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The investigators will determine the feasibility, safety and efficacy of intravenous sodium
      bicarbonate in reducing progression to overt acute renal failure in patients with the
      systemic inflammatory response syndrome, and low urine output or early acute renal impairment
      as defined by serum neutrophil gelatinase-associated lipocalin (NGAL).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00706771</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael C Reade, MBBS DPhil</name>
      <address>Austin &amp; Northern Hospitals, University of Melbourne</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>